BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65th Annual American Society of Hematology Meeting & Exposition (ASH).

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced a positive outcome of the interim futility analysis for HOPE-3, the pivotal Phase 3 trial evaluating CAP-1002 in patients with Duchenne muscular dystrophy (DMD).

IN8bio, Inc. announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors to raise up to $46.9 million at increasing valuations that includes initial gross proceeds of $14.4 million, extending the Company’s runway into 2025.

Inspira Technologies OXY B.H.N. Ltd. is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.

The Menarini Group and Stemline Therapeutics, Inc. presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments.

Therapeutic Solutions International, Inc., announced the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of the Company’s assets related to Amyotrophic Lateral Sclerosis, a progressive motor neuron degenerative disease for which no cure exists.

Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company.

Sirona Biochem Corp., is making a strategic move in the world of advanced skincare solutions.

More than 1,100 Community Health Centers - also called Federally Qualified Health Centers, or FQHC - provide affordable, comprehensive care to over 30 million children and adults across the United States.